• Publications
  • Influence
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
It is concluded that neither encainide nor flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia. Expand
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.
The use of moricizine in CAST-II to suppress asymptomatic or mildly symptomatic ventricular premature depolarizations to try to reduce mortality after myocardial infarction is not only ineffective but also harmful. Expand
Effects of low dose transdermal scopolamine on heart rate variability in acute myocardial infarction.
Low dose transdermal scopolamine safely increases cardiac parasympathetic activity and short-term heart rate variability after acute myocardial infarction and is a reasonable surrogate for improvement of long-term morbidity and mortality. Expand
Asymptomatic Cardiac Ischemia Pilot study (ACIP)
The ACIP study is a multicenter international pilot trial to determine the efficacy and safety of angina-directed medical therapy, angina plus ambulatory electrocardiographic-directedmedical therapy and revascularization and whether amelioration of asymptomatic ischemia improves survival and reduces cardiovascular morbidity. Expand
Evaluation of Myocardial Perfusion and Immune Cell Response in Cardiac Allograft Dysfunction of Heart-Transplant Patients
NGD shows decreased stress myocardial perfusion by cardiac MRI and a trend towards increased activated T cells in PBMCs, suggestive of an immune-mediated cause for allograft dysfunction. Expand
P1450Deep vein thrombosis after right sided catheter ablation; more common then previously thought?
It is suggested that DVT may occur at a high frequency then previously thought in this cohort and supports the consideration of peri-procedural prophylactic anticoagulation. Expand